Skip to content
Congress·In Committee·about 1 month ago

Senate Bill Would Require Mandatory Screening of Synthetic DNA Orders to Block Bioweapon Risk

Also known as: Biosecurity Modernization and Innovation Act of 2026

Legislative Progress

✓ Filed
Review
Senate
House
President

Impact Analysis

Scores: 1 = low, 5 = highSentiment: -5 to +5 (net benefit)

Key Points

  • This bill requires companies that sell synthetic DNA or DNA-making machines to screen every order. They must check if the DNA sequences being ordered match a list of 'sequences of concern' that could be used to create dangerous viruses or bacteria.
  • The policy affects biotechnology companies, researchers, and universities. Any person or group receiving federal funding would be banned from buying synthetic DNA from companies that do not follow these new security rules.
  • As DNA technology gets cheaper and faster, there is a growing risk that bad actors could order the building blocks for a new pandemic. This policy aims to replace voluntary guidelines with mandatory rules to make sure no one can secretly buy the parts for a bioweapon.
  • The government would use 'red-teaming'—sending fake suspicious orders—to test if companies are actually doing the screening. Companies that fail to follow the rules could face fines of up to $750,000 per violation.
  • To keep from slowing down legitimate science, the bill allows for 'fast-track' reviews for trusted institutions like universities. It also creates a 'sandbox' where new security tools can be tested without stopping regular research.
National Security Foreign PolicyTechnology DigitalHealthcare

Milestones

2 milestones2 actions
Jan 29, 2026Senate

Read twice and referred to the Committee on Commerce, Science, and Transportation.

Jan 29, 2026

Introduced in Senate

Related News

2 articles
Nextgov/FCW·24 days ago

Tech bills of the week: Restricting biometric use; expanding the quantum workforce; and more

The Biosecurity Modernization and Innovation Act, introduced by Sens. Klobuchar and Cotton, targets the misuse of gene synthesis technology by directing providers to screen orders for lethal pathogens and asking NIST to develop safety standards and best practices for the biotech sector.

C=
Eurasia Review·9 days ago

Governing Biotechnology’s Dual-Use Security Dilemma – Analysis

The US introduced the Biosecurity Modernization and Innovation Act to broaden the national biosecurity framework, taking cognisance of rapid advancements in the field and the risk of losing leadership to foreign adversaries while addressing the dual-use security dilemma in biotech.

CR~

Source Information

Document Type

Congressional Bill

Official Title

Biosecurity Modernization and Innovation Act of 2026

Bill NumberS 3741
Congress119th Congress
ChamberSenate
Latest ActionRead twice and referred to the Committee on Commerce, Science, and Transportation.

Sponsor

Cosponsors

(1)
D: 1

Analysis generated by AI. While we strive for accuracy, this should not be considered legal or professional advice. Always verify information with official government sources.